Publications by authors named "B Carazo-Gallego"
Background: Since the end of 2023, an elevated incidence and severity of Mycoplasma pneumoniae infections among children in Asia has been noted. Subsequently, this trend was observed in several European countries although limited data are currently available. We conducted a national study to delineate the ongoing M.
View Article and Find Full Text PDFIntroduction: Acute bronchiolitis is the main cause of hospitalization in children under 2 years of age, with a regular seasonality, mostly due to the respiratory syncytial virus.
Objectives: To describe the epidemiology of bronchiolitis hospitalizations in our center in the last 12 years, and analyze the changes in clinical characteristics, microbiology, and adverse outcomes during the SARS-CoV-2 pandemic.
Methods: Observational study including patients admitted for bronchiolitis between April 2010 and December 2021 in a Spanish tertiary paediatric hospital.
Infective endocarditis in paediatric patients from Andalusia (Spain), 2008-2020.
Enferm Infecc Microbiol Clin (Engl Ed)
November 2023
Introduction: Paediatric infective endocarditis (IE) is a serious condition associated with significant mortality. Information in Spain is limited and comes from case series from single centres. The aim was to describe the epidemiology, clinical features, microbiology and outcome of paediatric IE in Andalusia.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated how the introduction of the pneumococcal conjugate vaccine 13 (PCV13) affected the occurrence and types of invasive pneumococcal disease (IPD) in children in Andalusia between 2018 and 2020.
- The incidence of IPD initially rose slightly from 2018 to 2019 but then significantly decreased in 2020, with the cases attributed to PCV13 serotypes dropping from 28% compared to earlier years (2006-2009).
- Non-PCV13 serotypes such as 24F and 11A emerged as common strains during the study period, raising concerns about their potential for invasiveness and antibiotic resistance, indicating a need for ongoing
Article Synopsis
- The study investigates the effects of ruxolitinib, a JAK inhibitor, on patients with dominant-negative STAT3 (DN STAT3) syndromes, known for immune system issues similar to those seen in STAT1 gain-of-function (GOF) disorders.
- The research used various techniques to analyze the levels of STAT1 and its activated form (pSTAT1) in cells from DN STAT3 patients compared to healthy individuals, finding that DN STAT3 patients exhibit heightened STAT1 activity when stimulated by certain cytokines.
- Results showed that ruxolitinib successfully reduced cytokine-induced STAT1 signaling, suggesting its potential as a treatment option for patients with autoimmune or autoinflammatory symptoms associated with AD-HIES (Autosomal Dominant